We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

31 hedge funds and large institutions have $57.4M invested in Viridian Therapeutics in 2017 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

700% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 1

300% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 5

94% more funds holding

Funds holding: 16 → 31 (+15)

32% more capital invested

Capital invested by funds: $43.5M → $57.4M (+$13.9M)

0.29% more ownership

Funds ownership: 1.09% → 1.38% (+0.29%)

Holders
31
Holders Change
+15
Holders Change %
+93.75%
% of All Funds
0.77%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
20
Increased
8
Reduced
1
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BlackRock
BlackRock
New York
+$5.8M
2
Northern Trust
Northern Trust
Illinois
+$1.34M
3
State Street
State Street
Massachusetts
+$1.19M
4
Goldman Sachs
Goldman Sachs
New York
+$645K
5
TCIM
TIAA CREF Investment Management
New York
+$396K

Top Sellers

1
Millennium Management
Millennium Management
New York
-$811K
2
DY
Dowling & Yahnke
California
-$498K
3
HighTower Advisors
HighTower Advisors
Illinois
-$302K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$177K
5
SCM
Segantii Capital Management
Hong Kong
-$77K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$40.4M – – –
BlackRock
2
BlackRock
New York
$6.67M +$5.8M +34,381 +429,763%
Goldman Sachs
3
Goldman Sachs
New York
$1.58M +$645K +3,823 +88%
Northern Trust
4
Northern Trust
Illinois
$1.54M +$1.34M +7,957 New
State Street
5
State Street
Massachusetts
$1.37M +$1.19M +7,070 New
UOTTAIMCU
6
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
$1.36M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$532K +$346K +2,050 +295%
TCIM
8
TIAA CREF Investment Management
New York
$455K +$396K +2,344 New
Geode Capital Management
9
Geode Capital Management
Massachusetts
$398K +$212K +1,258 +158%
Bank of New York Mellon
10
Bank of New York Mellon
New York
$355K +$309K +1,832 New
TA
11
Teachers Advisors
New York
$322K +$281K +1,662 New
Citigroup
12
Citigroup
New York
$302K +$263K +1,556 New
California State Teachers Retirement System (CalSTRS)
13
California State Teachers Retirement System (CalSTRS)
California
$290K +$252K +1,493 New
Charles Schwab
14
Charles Schwab
California
$276K +$240K +1,420 New
Deutsche Bank
15
Deutsche Bank
Germany
$185K +$163K +965 New
New York State Common Retirement Fund
16
New York State Common Retirement Fund
New York
$175K +$152K +900 New
RhumbLine Advisers
17
RhumbLine Advisers
Massachusetts
$156K +$136K +805 New
Morgan Stanley
18
Morgan Stanley
New York
$150K +$70.6K +418 +118%
PAM
19
Panagora Asset Management
Massachusetts
$148K +$125K +743 +3,538%
HighTower Advisors
20
HighTower Advisors
Illinois
$143K -$302K -1,788 -71%
State of Wisconsin Investment Board
21
State of Wisconsin Investment Board
Wisconsin
$129K +$113K +667 New
AIG
22
American International Group
New York
$101K +$88.1K +522 New
NFA
23
Nationwide Fund Advisors
Ohio
$84K +$73.3K +434 New
PCM
24
Prelude Capital Management
New York
$76K +$7.93K +47 +14%
Barclays
25
Barclays
United Kingdom
$51K +$21.6K +128 +95%
1
2

VRDN Hedge Fund Activity: Q2 2017 in Review

31 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q2 2017, worth a combined $57.4M — up 32% from $43.5M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new VRDN positions and 5 closed out — a net gain of 15 holders — while 8 added to existing stakes and 1 trimmed.

The largest buyer was BlackRock, adding an estimated $5.8M. The largest seller was Millennium Management, exiting entirely with an estimated $811K sold.

  • 31 institutional investors held Viridian Therapeutics (VRDN) as of Q2 2017, up from 16 in Q1 2017.
  • Funds reported $57.4M of Viridian Therapeutics stock for Q2 2017, up 32% quarter-over-quarter.
  • 20 funds opened new Viridian Therapeutics positions in Q2 2017 and 5 closed out, a net change of +15 holders.
  • The largest Viridian Therapeutics buyer in Q2 2017 was BlackRock, an estimated $5.8M added.
  • The largest Viridian Therapeutics seller in Q2 2017 was Millennium Management, an estimated $811K sold.

Based on aggregated 13F filings for Q2 2017.